Targeted Protein Degradation Therapy Research and Development

Targeted protein degradation (TPD) is a promising strategy that makes use of the cell's own protein degradation systems, including the ubiquitin-proteasome system (UPS). It offers an effective route to reducing off-target effects, to overcoming drug resistance, and to directing targeted therapeutics at proteins that have conventionally been considered undruggable and that small molecule inhibitors have been unable to address. Research on proteolysis targeting chimeras (PROTACs) and molecular glues (MGs) has grown accordingly, since both promote protein degradation through the UPS, a pathway that tags proteins for breakdown through an enzymatic cascade.

PROTACs act through a ternary complex formed by a ligand that binds the target protein, an E3 ligase ligand, and a linker. This approach degrades a wide range of proteins specifically and allows PROTACs to be recycled, which raises their efficacy. MGs are small molecule compounds that modulate protein-protein interactions (PPIs) to promote the interaction between an E3 ligase and a target protein, thereby accelerating degradation of that target. Their smaller structures and simpler mechanism give MGs better cell permeability and potential advantages for oral administration. Because PPIs are difficult to predict, many MGs have been discovered by chance.

PROTAC development follows a defined sequence of steps. A program first establishes which ligase and which E2 enzyme can ubiquitinate the target protein, then assembles candidate molecules from ligands, linkers and warheads, then tests whether those molecules promote ubiquitination in a reconstituted reaction, then confirms degradation in cells, and finally resolves the chain linkage mechanism behind the result. Reference degraders serve as controls in the cellular evaluation step. Amerigo Scientific provides high quality research products for each stage to advance the development of protein degraders.

Target and E3 Ligase Assessment

In the research and development of TPD therapy, whether the intended target can be ubiquitinated by a system that can be reconstituted in vitro, and which E3 ligase and matching E2 partner will carry the reaction are two key questions. Amerigo Scientific offers assay kits to answer both at the enzyme level, and the individual cascade enzymes are available separately for laboratories building a system around a specific ligase.

Degrader Design and Synthesis

A proteolysis targeting chimera is assembled from a ligand that recruits the E3 ligase, a warhead that binds the target, and a linker that sets the distance and orientation between them. Linker length and terminal chemistry are the variables a series revisits most often, and conjugates that arrive with the ligase ligand and linker already joined shorten each round to a single coupling step.

Biochemical Evaluation

Once candidate molecules exist, the question becomes whether a given compound drives ubiquitination of the target, and how efficiently it does so relative to others in the series. Amerigo Scientific offers in vitro ubiquitination assay kits and E3 ligase activity assay kits that answer this with defined components ahead of cellular work. Ubiquitin variants allow the reaction itself to be tuned to the question being asked, and purified proteasomes extend the same reconstituted approach from ubiquitination through to degradation.

Cellular Degradation Assessment

Activity in a reconstituted reaction establishes chemical competence, and the next step measures what happens inside cells. Capturing the polyubiquitinated fraction of a lysate and detecting the target within it turns the readout into a number, which makes dose response and compound ranking practical at plate scale. Degraders with established behavior run alongside as controls, and the proteasome and ubiquitin binding proteins supply the machinery and the capture reagents behind these measurements.

Mechanism and Linkage Analysis

Ubiquitin forms chains through seven lysine residues and through its N-terminus, and the linkage determines the outcome. K48-linked chains route a substrate to the proteasome while K63-linked chains act in signaling, so establishing chain type confirms that an observed modification corresponds to the degradation route the compound was designed to use. Defined ubiquitin chains and deubiquitinases are the reference substrates and the enzymatic tools behind that analysis.